This weakens ASE of PTK2 mediated by SRSF1 (the effector of SRSF1 carcinogenic activity), leading to a decrease in PTK2 mRNA and protein expression, and thereby inhibiting cell proliferation, migration, and survival in tumor progression.234,235. The gene discussed is PTK2; the disease is neoplasm.